Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: Mol Cancer Ther. 2019 Jun 21;18(9):1615–1627. doi: 10.1158/1535-7163.MCT-18-0706

Figure 3. PLK1 inhibition promotes B-ALL specific cell death and is associated p53 accumulation.

Figure 3.

(A) Primary cells from B-ALL (left) and T-ALL (right) patients (each n=3) were transduced with doxycycline- inducible PLK1 or scrambled shRNAs and cultured in low-dose doxycycline (2 μg/mL). Cell viability was determined on days 1 and 4 by trypan blue staining. (B) The PLK1-shRNA knockdown was confirmed both at the RNA and protein level by qRT-PCR and Western blot, respectively. PLK1 RNA was significantly reduced in both B-ALL patient samples (p<0.05, n=3) by two sample t-tests. (C) Representative flow cytometry data summarizing the differences in intracellular p53 expression from a T-ALL and 5 B-ALL patient samples transduced with the PLK1 or scrambled shRNA after 48 hours.